Neurological safety of oxaliplatin in patients with uncommon variants in Charcot-Marie-tooth disease genes
Le-Rademacher J, Lopez C, Kanwar R, Major-Elechi B, Abyzov A, Banck M, Therneau T, Sloan J, Loprinzi C, Beutler A. Neurological safety of oxaliplatin in patients with uncommon variants in Charcot-Marie-tooth disease genes. Journal Of The Neurological Sciences 2020, 411: 116687. PMID: 32018185, PMCID: PMC7096263, DOI: 10.1016/j.jns.2020.116687.Peer-Reviewed Original ResearchConceptsChemotherapy-induced peripheral neuropathyRisk of CIPNTooth disease (CMT) genesCIPN riskCharcot-MariePatient-reported outcome instrumentsSingle nucleotide variantsFavor of casesNeurological safetyCommon genetic testsNeurotoxic chemotherapyOxaliplatin therapyPeripheral neuropathyChemotherapy decisionsClinical guidanceOutcome instrumentsUncommon variantPatientsNon-synonymous single nucleotide variantsSignificant associationOxaliplatinGenetic testsRiskCommon single nucleotide variantsCMT